


## Newsletter | Life Sciences: What's new in Europe?

A legal update on recent developments in the life sciences sector



### Antitrust

#### The Servier case: The game isn't over yet

The European Court of Justice recently issued seven judgments in the landmark "Servier" case, confirming the anticompetitive nature of "pay-for-delay" agreements between originator and generic companies. However, the case is not fully resolved, as part of it was referred back to the General Court. This decision underscores the strict scrutiny of anticompetitive practices in the pharmaceutical industry and its impact on market strategies.

[Read more »](#)



### Corporate Finance

#### Overview of financing options for French biotech companies

French biotech companies navigate unpredictable markets with various financing tools. Discover the diverse financing avenues available to them, from equity securities to strategic partnerships, and learn how they adapt to market challenges.

[Read more »](#)



### Regulatory

#### Health is priceless; supply shortages come at a high price, as determined by the sanctions imposed by the French Health Agency

France has enforced mandatory safety stock requirements for essential drugs since 2021. In September 2024, the French Health Agency (ANSM) fined 11 companies a total of 8 million euros for non-compliance with the 4-month safety stock. These unprecedented sanctions aim to deter shortages. What are the key takeaways for companies?

[Read more »](#)



## Antitrust

### llumina/Grail: EU court overturns approach to “killer acquisitions”

In a much-anticipated ruling, the EU's highest court invalidated the European Commission's policy on "killer acquisitions," forcing the Commission to devise a new approach. Explore the context of the case, details behind the court's decision, and practical implications it could have.

[Read more »](#)




## Regulatory

### Healthcare center investor saga: French court rules on minority shareholding by non-healthcare professionals

The French administrative supreme court has issued a ruling on minority shareholding by non-healthcare professionals in medical centers, drawing from a precedent in the veterinary sector. Read more to find out what this decision means for the conditions for effective control of medical centers by physicians, an issue with significant financial stakes.

[Read more »](#)


## Contacts



**Alain Decombe**  
Partner  
Paris



**Mélanie Thill-Tayara**  
Partner  
Paris



**Laurence Bary**  
Partner  
Paris



**Michael I. Okkonen**  
Partner  
Brussels



**Sophie Pelé**  
Partner  
Paris



**Clemens Graf York von Wartenburg**  
Partner  
Brussels



**Marion Provost**  
National Partner  
Paris



**Alec Burnside**  
Senior Counsel  
Brussels

## About Dechert's life sciences group

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. Our nearly 1,000 lawyers across 20 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.

A key component of the firm's strategy in Europe, Dechert's Paris office is active in antitrust/competition and European law, corporate/M&A, financial services and asset management, financing, intellectual property, labor and employment, litigation and compliance, regulatory and tax.

Our life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments.

[Learn more »](#)

### Photo credits

This email was sent to **your details**. Please do not forward this email to any third-party recipients. Certain hyperlinks within this email will link directly to your personal details and marketing preferences. If you would like to share this email, please use the relevant share buttons available at the top of this email.

[Print email](#) / [Unsubscribe](#) / [Update your marketing profile](#)

© 2024 Dechert LLP. All rights reserved. This publication should not be considered as legal opinions on specific facts or as a substitute for legal counsel. It is provided by Dechert LLP as a general informational service and may be considered attorney advertising in some jurisdictions. Prior results do not guarantee a similar outcome. We can be reached at the following postal addresses: in the U.S.: 1095 Avenue of the Americas, New York, NY 10036-6797 (+1 212 698 3500); in Hong Kong: 31/F Jardine House, One Connaught Place, Central, Hong Kong (+852 3518 4700); and in the UK: 25 Cannon Street, London EC4M 5UB (+44 20 7184 7000).

Dechert internationally is a combination of separate limited liability partnerships and other entities registered in different jurisdictions. Further details including how to contact us can be found at [dechert.com](http://dechert.com) or on our [Legal Notices page](#).